Literature DB >> 10353864

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.

O Pontesilli1, S Kerkhof-Garde, D W Notermans, N A Foudraine, M T Roos, M R Klein, S A Danner, J M Lange, F Miedema.   

Abstract

Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodeficiency virus type 1 (HIV-1) Gag and frequencies of circulating HIV-1-specific cytotoxic T lymphocyte precursors (CTLps) were measured in 12 patients undergoing highly active antiretroviral therapy (HAART) after long-standing HIV-1 infection. LPRs to at least 1 recall Ag became detectable or increased in all patients during HAART. No significant LPRs to Gag-p24 were observed, whereas 4 of 8 patients tested presented with Gag-p17-specific LPRs. HIV-1-specific CTLp frequencies became measurable or increased early during therapy in 6 of 10 patients tested and were maintained or decreased thereafter. Increasing HIV-1-specific CTLp frequencies were seen only in association with partial HAART failure in 1 patient. In conclusion, restoration of CD4+ T lymphocyte responsiveness to recall Ags is achieved during HAART. The data provide evidence for limited HIV-1-specific CD4+ memory T cells during advanced HIV-1 infection and suggest that both CD4+ and CD8+ HIV-1-specific T cells are poorly stimulated when viral load is suppressed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353864     DOI: 10.1086/314837

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

Review 1.  Immunofluorescence analysis of T-cell responses in health and disease.

Authors:  H T Maecker; V C Maino; L J Picker
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Authors:  D Scott-Algara; J P Aboulker; C Durier; E Badell; F Marcellin; M Prud'homme; C Jouanne; V Meiffredy; F Brun-Vezinet; G Pialoux; F Raffi
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 3.  Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.

Authors:  P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

5.  Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.

Authors:  Michael P Weekes; Mark R Wills; J G Patrick Sissons; Andrew J Carmichael
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

6.  CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.

Authors:  X L Huang; Z Fan; C Kalinyak; J W Mellors; C R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

7.  Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness.

Authors:  G A D Hardy; N Imami; A K Sullivan; A Pires; C T Burton; M R Nelson; B G Gazzard; F M Gotch
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

8.  Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.

Authors:  M A Altfeld; B Livingston; N Reshamwala; P T Nguyen; M M Addo; A Shea; M Newman; J Fikes; J Sidney; P Wentworth; R Chesnut; R L Eldridge; E S Rosenberg; G K Robbins; C Brander; P E Sax; S Boswell; T Flynn; S Buchbinder; P J Goulder; B D Walker; A Sette; S A Kalams
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

Authors:  Daria Trabattoni; Sergio Lo Caputo; Mara Biasin; Elena Seminari; Massimo Di Pietro; Giovanni Ravasi; Francesco Mazzotta; Renato Maserati; Mario Clerici
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 10.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.